Group 1 - Nanjing Pharmaceutical (688189) experienced a significant stock price increase, reaching 17.14 CNY per share with a rise of 20.03% [1] - The company announced plans to acquire a domestic pharmaceutical technology asset group, although it is uncertain if this will constitute a major asset restructuring [1] - The acquisition is still in the planning stage, and no formal agreements have been signed, indicating substantial uncertainty regarding its successful implementation [1]

Core Viewpoint - Hunan Nanxin Pharmaceutical Co., Ltd. experienced a significant stock price fluctuation, with a cumulative increase of 30% over three consecutive trading days, prompting the company to disclose information regarding its ongoing asset acquisition plans and the normalcy of its operations [2][3]. Group 1: Stock Trading Anomaly - The company's stock price increased by a cumulative 30% over three trading days (July 28, 29, and 30, 2025), which is classified as an abnormal trading situation according to the Shanghai Stock Exchange regulations [2][3]. - The company is currently planning to acquire a domestic pharmaceutical technology asset group, but it is uncertain whether this will constitute a major asset restructuring [2][5]. Group 2: Company Operations and Major Events - The company conducted a self-inspection and confirmed that its daily operations are normal, with no significant changes in the market environment or industry policies [4]. - As of the announcement date, there are no undisclosed major events related to the company, aside from the ongoing acquisition plans [5]. Group 3: Media and Market Rumors - The company has not identified any recent media reports that could have significantly impacted its stock price [6]. Group 4: Board Statement and Commitments - The board of directors confirmed that there are no undisclosed matters that should be reported according to the relevant regulations, and they have not been made aware of any information that could significantly affect the company's stock price [7].

公告显示，南新制药股票交易连续三个交易日内（7月28日—30日）收盘价格涨幅偏离值累计达到 30%，根据《上海证券交易所交易规则》《上海证券交易所科创板股票异常交易实时监控细则》的有关 规定，属于股票交易异常波动的情形。7月30日，南新制药收涨20%，收盘价为14.28元/股。 北京商报讯（记者 丁宁）7月30日晚间，南新制药（688189）发布公告称，公司近期正在筹划购买某一 国内药品技术等资产组事项，尚无法确定是否构成重大资产重组。该事项正处于筹划阶段，尚未签署任 何有关收购的意向协议，是否能够顺利实施存在重大不确定性。公司将根据该事项的进展情况及时履行 信息披露义务，具体内容以公司后续公告为准。 ...

人民财讯7月30日电，南新制药(688189)7月30日晚间发布股票交易异常波动公告称，近期正在筹划购买 某一国内药品技术等资产组事项，尚无法确定是否构成重大资产重组。该事项正处于筹划阶段，尚未签 署任何有关收购的意向协议，是否能够顺利实施存在重大不确定性。敬请广大投资者理性投资，注意风 险。 ...

南新制药：近期正筹划购买某一国内药品技术等资产组事项 尚无法确定是否构成重大资产重组 智通财经7月30日电，南新制药(688189.SH)公告称，公司股票交易连续三个交易日内收盘价格涨幅偏离 值累计达到30%，属于股票交易异常波动的情形。公司近期正在筹划购买某一国内药品技术等资产组事 项（简称"本次交易"），尚无法确定是否构成重大资产重组。该事项正处于筹划阶段，尚未签署任何有 关收购的意向协议，是否能够顺利实施存在重大不确定性。公司将根据该事项的进展情况及时履行信息 披露义务，具体内容以公司后续公告为准。敬请广大投资者理性投资，注意风险。 ...

南新制药发布股票交易异常波动公告，公司股票交易连续三个交易日内(2025年7月28日、7月29日和7月 30日)收盘价格涨幅偏离值累计达到30%，根据相关规定，属于股票交易异常波动的情形。公司近期正 在筹划购买某一国内药品技术等资产组事项，尚无法确定是否构成重大资产重组。该事项正处于筹划阶 段，尚未签署任何有关收购的意向协议，是否能够顺利实施存在重大不确定性。公司将根据该事项的进 展情况及时履行信息披露义务。 ...